Abstract
BackgroundAll‐cause mortality has been suggested as an end‐point in cancer screening trials in order to avoid biases in attributing the cause of death. The aim of this study was to investigate which sample size and follow‐up is needed to find a significant reduction in all‐cause mortality.MethodsA literature review was conducted to identify previous studies that modeled the effect of screening on all‐cause mortality. Microsimulation modeling was used to simulate breast cancer, lung cancer, and colorectal cancer screening trials. Model outputs were: cancer‐specific deaths, all‐cause deaths, and life‐years gained per year of follow‐up.ResultsThere were large differences between the evaluated cancers. For lung cancer, when 40 000 high‐risk people are randomized to each arm, a significant reduction in all‐cause mortality could be expected between 11 and 13 years of follow‐up. For breast cancer, a significant reduction could be found between 16 and 26 years of follow‐up for a sample size of over 300 000 women in each arm. For colorectal cancer, 600 000 persons in each arm were required to be followed for 15‐20 years. Our systematic literature review identified seven papers, which showed highly similar results to our estimates.ConclusionCancer screening trials are able to demonstrate a significant reduction in all‐cause mortality due to screening, but require very large sample sizes. Depending on the cancer, 40 000‐600 000 participants per arm are needed to demonstrate a significant reduction. The reduction in all‐cause mortality can only be detected between specific years of follow‐up, more limited than the timeframe to detect a reduction in cancer‐specific mortality.
Highlights
Cancer screening trials generally use cancer‐specific mortality as an endpoint.[1,2] This has been criticized because of possible biases in determination of the cause of death.[1,3,4] The first is slippery linkage bias: screening or the resulting diagnosis or treatment may lead to deaths that cannot be linked to the screening
We modeled populations with a uniform age distribution among the eligible screening ages at the start of each trial, because most trials are designed that way
The results show that cancer screening trials are potentially able to demonstrate a significant reduction in all‐cause mortality due to screening, as long as the sample sizes of the trials are very large
Summary
Cancer screening trials generally use cancer‐specific mortality as an endpoint.[1,2] This has been criticized because of possible biases in determination of the cause of death.[1,3,4] The first is slippery linkage bias: screening or the resulting diagnosis or treatment may lead to deaths that cannot be linked to the screening. The results of this study can be used to inform the debate on all‐cause mortality as an endpoint of screening trials
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
